Radio what’s new? Tuning in to turning cancer cells off
Tuning in to the field of targeted cancer medicine through molecular radiotherapy or targeted radionuclides.
Tuning in to the field of targeted cancer medicine through molecular radiotherapy or targeted radionuclides.
Chaired by Tara Raveendran of Shore Capital. Speakers from Asceneuron, Storm Therapeutics, Theragnostics & Macrophage.
Chris Sterling appointed as Non-Executive Director & Radiopharmaceutical drug development expert Dr Daniel Stevens joins as Chief Medical Officer LONDON, UK, 14 November 2019 – Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, announces two strategic hires to its leadership team with the appointment of Dr Daniel Stevens […]